Indications for Ado-trastuzumab emtansine

Ado-trastuzumab emtansine is marketed in China under the brand name Hercelet. Trastuzumab is an injectable solution used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have been previously treated with other drugs (such as trastuzumab, taxanes) that did not respond well, or whose cancer has returned during or within 6 months of completing treatment. It is also used as an add-on treatment for patients with HER2-positive early-stage breast cancer who still have cancer after treatment with taxane drugs and trastuzumab.